birinapant (IGM-9427) / IGM Biosciences 
Welcome,         Profile    Billing    Logout  
 55 Diseases   1 Trial   1 Trial   295 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
birinapant (IGM-9427) / IGM Biosciences
NCT03809208: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
1
34
US
Birinapant, Intensity modulated re-irradiation therapy (IMMRT)
National Cancer Institute (NCI)
Head Cancer, Facial Cancer, Neck Cancer, Upper AerodigestiveTract Cancer, Oral Cancer
10/20
10/21
NCT03803774: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Terminated
1
13
US
Birinapant, TL32711, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Tumor Biopsy, PET Scan, Positron emission tomography scan, CT Scan, Computed tomography scan, MRI Scan, Magnetic resonance scan
National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
11/23
12/23
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
birinapant (IGM-9427) / IGM Biosciences
NCT03809208: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
1
34
US
Birinapant, Intensity modulated re-irradiation therapy (IMMRT)
National Cancer Institute (NCI)
Head Cancer, Facial Cancer, Neck Cancer, Upper AerodigestiveTract Cancer, Oral Cancer
10/20
10/21
NCT03803774: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Terminated
1
13
US
Birinapant, TL32711, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Tumor Biopsy, PET Scan, Positron emission tomography scan, CT Scan, Computed tomography scan, MRI Scan, Magnetic resonance scan
National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
11/23
12/23
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
01/25
01/25

Download Options